The effect of vitamin D in vitiligo patients

Phase 1

Conditions: Vitiligo.
Vitiligo

Registration Number: IRCT2017031133014N1

Lead Sponsor: Vice chancellor for research, Ahvaz Jundishapur University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 24

Inclusion Criteria

patients with generalized vitiligo or skin lesions equal or more than five percent of the body surface. Exclusion criteria: patients with hemodialysis and renal failure; receiving thiazide diuretics, lithium utilization; get systemic treatment in the last month; increasing serum leading to drug toxicity; age under 6 years old; phototherapy sessions less than 2 times a week.

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in the extent of skin involvement. Timepoint: Every 2 months until 4 months. Method of measurement: Based on Vitiligo Area Scoring Index (VASI) Score. In this method body is divided into five separate regions: the hands, upper extremities, trunk,lower extremities and feet. The face and neck areas are assessed separately. One hand unit of the patient (the palm plus the volar surface of the digits) is used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. For each body region, VASI is determined as the product of the vitiligo area in hand units (set at 1% per unit) and the pattern of depigmentation within each hand-unit-measured patch (possible values of 10, 25,50, 75, 90 or 100%, which are illustrated with a descrip-tive atlas of patient photographs). VASI, applied to the whole body, will calculated using the following formula, (possible range 0–100): all body sites (hand units) × depigmentation.

Secondary Outcome Measures